Biotech News
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025
ir.lyell.com2026-05-06 14:57 EST
Acquired exclusive global rights to LYL273, a novel GCC-targeted CAR T-cell product candidate that has demonstrated a 67% overall response rate, an 83% disease control rate and a manageable safety profile at the highest dose level studied to date in patients with refractory metastatic colorectal